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Abstract
Background: The prevalence of atrial fibrillation (AF) is increasing world wide and amongst
factors that aggravate the risk is diabetes mellitus (DM), also in epidemic development.
However, although DM is a potentially modifiable risk factor for AF, few, if any, studies have
explored the prevalence of undiagnosed dysglycaemia among subjects with AF or if duration of AF
are related to parameters of glycaemia or dysglycaemia prevalence.
Methods: In this case control study, amongst 75-year old subjects with and without AF, the
prevalence of dysglycaemia, i.e., impaired fasting glycaemia, impaired glucose tolerance or DM,
according to World Health Organisation criteria was assessed by a 75-g oral glucose tolerance test
(OGTT).
Results: Prevalence of undiagnosed DM among the 108 subjects (male/female 73/35, BMI 25.4 ±
3.2) without and the 46 (male/female 34/12, BMI 25.3 ± 3.7) with AF (median AF duration five years)
where 3.7% and 13.0%, respectively (p = 0.031, Odds ratio (OR) 3.86 (95% Confidence interval
[CI]: 1.01, 16.25)) whereas the overall prevalence of dysglycaemia (prediabetes and DM) where
similar (respectively 43.5% and 39.1%, p = 0.46, OR 0.83 [95% CI: 0.41, 1.69]). Patients with AF
duration ≥ 5 years had however a higher dysglycaemia prevalence (61.1% [DM 22.2%, prediabetes
38.9%]) as compared to AF duration < 5 years (25% [DM 7.1%, prediabetes 17.9%], p = 0.0014, OR
4.7 [95% CI: 1.30, 16.90]) or no AF (p = 0.17, OR 2.04 [95% CI: 0.73, 5.66]). There was also a
significant correlation between the duration of AF and HbA1c (r = 0.408, p = 0.005) and fasting
glucose levels (r = 0.353, p = 0.016).
Conclusion:  AF is associated with chronic hyperglycaemia amongst 75-year old subjects.
Prediabetes and DM should be pro-actively assessed if AF duration ≥ 5 years.
Background
The prevalence of atrial fibrillation (AF) doubles with
each decade of age in the elderly [1], which is attributed to
accompanying cardiac abnormalities occurring [2],
although also linked to other independent AF risk factors
(some which also are increasing with age), e.g., prior AF,
male sex, depressed ejection fraction, hypertension, atrial
enlargement, valvular heart surgery, chronic renal insuffi-
ciency, rheumatic heart disease, obesity and inflamma-
tion [1,3,4]. Today, AF affects about 8% of subjects aged
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65 or older [5], and due to the ageing population, a 2.5
fold increase in AF prevalence during the next 50 years has
been suggested [6].
One concern added to this is that one potentially modifi-
able risk factor for AF, namely diabetes mellitus (DM),
also is occurring with growing prevalence globally [7].
DM is a relative strong AF risk factor and renders patients
approximately 1.4–2.1 times more prone to develop AF
[8-10]. Hence, the growing prevalence of DM could fur-
ther aggravate the projected increase in AF prevalence [6].
Although DM account for 10–25% of AF patients [8-10],
and the fact that the increased incidence of AF is not only
limited to those with established or new-onset DM [10],
but even also affects patients, at least during cardiac sur-
gery, with lesser degrees of hyperglycaemia [11], few stud-
ies have investigated whether interventions reducing the
blood glucose levels could reduce the AF burden. How-
ever, some reports supports that this could be the case, e.g.
a 1600 kcal/day diet and walking three times/day for more
than 30 min have been reported to eliminate paroxysmal
AF after six months in an older women [12] and lowering
blood glucose with insulin during cardiac surgery have
been associated with lower AF incidence [13], although
debated [14]. Regression of paroxysmal AF has also been
reported with rosiglitazone treatment (a peroxisome pro-
liferator receptor activator indicated for the treatment of
hyperglycaemia in type 2 DM) in two patients [15].
Hence the detection of glucose disturbances in AF for
these reasons could be of importance. Perhaps more
importantly though, is that hyperglycaemia among sub-
jects with AF contributes to an added risk for stroke [16]
and convincing data now support aggressive glucose con-
trol to prevent stroke in patients with DM [17].
However, few, if any, studies have investigated the preva-
lence of undiagnosed abnormal glucose metabolism in
patients with AF, in contrast to investigations among
patients with cardiovascular (CV) disorders [18,19] where
this consistently have been reported higher than 50%,
twice that of age matched controls [18].
Given the association between hyperglycaemia as a risk
factor for AF and hyperglycaemia being modifiable, we
assessed the glycaemic status (as defined according to an
oral glucose tolerance test [OGTT]) among older patients
with AF and age-matched controls without, all being pre-
viously undiagnosed with abnormal glucose metabolism.
Furthermore, we investigated whether the duration of AF
could be related to parameters of glycaemia or dysglycae-
mia prevalence.
Methods
This study was conducted at the Asker and Baerum Hospi-
tal in Eastern Norway as a sub-study of the Asker and
Baerum Atrial Fibrillation study [20], an epidemiological
study of AF in all 75-year old men and women (born in
the year 1930) who were permanent residents of the cov-
erage area of hospital (n = 1117), where 82% (n = 916)
attended. In the present case-control study we assessed the
prevalence of previously undiagnosed abnormal glucose
metabolism among subjects with and without AF through
an OGTT. In addition, other glucometabolic parameters
were measured in plasma, as well as measurement of
anthropometric parameters and blood pressure. Collec-
tion of medical history and current use of medication
were recorded from questionnaires and interview.
The participants for this study were consecutively
recruited when identified with AF on a first-come first-
serve basis, and for each subject with AF that agreed to par-
ticipate, the next two subjects in sinus rhythm of the same
gender were recruited as control subjects. Exclusion crite-
ria were neurological deficits or other medical conditions
resulting in incapability of performing an OGTT, a previ-
ous diagnosis of prediabetes, e.g., impaired fasting glycae-
mia (IFG) or impaired glucose tolerance (IGT), DM or a
history of gestational DM, an unstable medical condition
or an acute or chronic illness known to influence OGTT
(e.g. infection).
The protocol was approved by the Regional Committee
for Medical Research Ethics, Norway and by the Norwe-
gian Data Inspectorate. Each subject gave informed writ-
ten consent before participating in the study. No
compensation was given for the participation in the study.
Glucometabolic parameters and definition of the 
metabolic syndrome
An OGTT with ingestion of 75 g. glucose dissolved in 300
ml water flavoured with citric acid was performed accord-
ing to WHO standards, but with the supplement of a 1
hour (h) – glucose measurement. Blood glucose during
the OGTT was analyzed immediately in capillary whole
blood (photometer; HemoCue, Ängelholm, Sweden).
HbA1c was analysed by colorimetric and immunoturbidi-
metrical methods (COBAS INTEGRA system, Roche Diag-
nostics, Mannheim, Germany) in whole blood with an
upper normal limit reference value of 6.2%.
Area under the curve (AUC) for the OGTT was calculated
as a measure of glycaemic burden, and was assessed by
calculating the incremental area from start to 1 h and from
1 h to 2 h [21].Cardiovascular Diabetology 2008, 7:28 http://www.cardiab.com/content/7/1/28
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Insulin was analyzed by radioimmunoassay using an anti-
body with no cross-reaction against proinsulin (Diagnos-
tic System Laboratories, Webster, TX). The homeostasis
model assessment for insulin resistance (HOMA-IR) was
calculated in fasting conditions as plasma insulin (pmol/
l) × blood glucose (mmol/l) × 1.13 (correction for plasma
glucose)/135 [22]. The median (interquartile range) for
HOMA-IR in the reference group (the 75-year old subjects
without AF) were 3.56 (2.76–4.96).
In this study, subjects without normal glucose tolerance
(NGT) are referred to as being dysglycaemic, or having an
abnormal glucose metabolism, i.e. prediabetes (IFG and/
or IGT) or DM according to World Health Organisation
criteria [23]. Metabolic syndrome was defined according
to the National Cholesterol Education Program's Adult
Treatment Panel III classification [24].
Lipid parameters
Serum levels of total cholesterol, high-density lipoprotein
(HDL)-cholesterol and triglycerides (TG) were measured
enzymatically on a Roche/Hitachi 917 analyzer (Roche
Diagnostics). Low-density lipoprotein (LDL)-cholesterol
was calculated using the Friedewald formula.
ECG and classification of hypertension
AF was assessed by twelve lead ECG that were recorded in
the supine position after 5 min rest as described previ-
ously [19]. In patients currently in sinus rhythm, but with
a history of AF, supplementary information was retrieved
from hospital and general practitioners' records. Duration
of AF was calculated based on year since first physician's
diagnosis of AF.
Blood pressure was measured in the supine position after
10 min rest. If the initial blood pressure was greater than
160/95 mm Hg, a repeat measurement was done, and the
lowest measurement was registered. Hypertension was
defined as systolic/diastolic blood pressure > 140/90
mmHg or current use of any antihypertensive medication.
Blood sampling protocol
Peripheral venous blood was drawn between 8 and 10 AM
after an overnight fast and serum and plasma were col-
lected as previously described [18]. The samples were ana-
lysed within 24 hours (routine chemistry, lipid and
glucose parameters) or stored at -70°C until analysis
(insulin).
Statistics
Sample sizes where calculated based on an expected prev-
alence of undiagnosed dysglycaemia in the AF group of
50% [18,19] and in the controls of 25% [15]. Our null
hypothesis was that there should be no difference in this
prevalence between subjects with AF and controls. As we
wanted a statistical power of 80% and an alpha error level
of 5%, we then needed at least 45 individuals in each
group. Data analysis was performed using SPSS statistical
software version 14.0.1 for Windows (SPSS Inc.). Results
for continuous variables are presented as mean and stand-
ard deviation unless otherwise stated. Between-group sta-
tistical analysis of continuous parameters utilized
student's t-test or one-way ANOVA. Correlation coeffi-
cients are univariate derived using Spearman's correlation.
Categorical variables are presented as counts or propor-
tions (%) and statistical comparisons of these parameters
were carried out by chi-squared test or the Fischer exact
test. Odds ratio (OR) with 95% confidence interval (CI)
was estimated for dysglycaemia and impact of congestive
heart failure and valve surgery on dysglycaemia preva-
lence and atrial fibriallation duration was investigated in
a logistic regression analysis. P-values were two-sided and
considered significant when < 0.05.
Results
We recruited 61 subjects with AF and 126 without of
whom 13 had a previous diagnosis of DM (seven with AF
and six without [p = 0.091]) and were excluded from the
analysis. Hence, in total 54 subjects with AF and 120 sub-
jects without AF were eligible. Among these, 154 agreed to
perform the OGTT of whom 46 (30.3%) had AF (paroxys-
mal in 15 [32.6%], persistent or chronic in 26 [56.5%]
and newly diagnosed in five [10.9%]). The median AF
duration was five years (min 0, max 28).
All study participants were living in their own home, i.e.
none were institutionalised, and further background char-
acteristic and use of medications are given in table 1. As
outlined, 3/4 of the subjects with AF received warfarin,
while only four subjects without AF received this. This lat-
ter was due to previous heart valve surgery (n = 1), deep
vein thrombosis (n = 1) and myocardial infarction (n =
2).
In total six previously undiagnosed cases of DM (13.0%)
were detected among subjects with AF as compared to
four (3.7%) among those without AF (p = 0.031, OR 3.86
[95% CI: 1.01, 16.25], table 2), whereas no differences in
the prevalence of prediabetes (IFG/IGT) were found.
Hence, the total prevalence of dysglycaemia among sub-
jects with AF overall, where similar as among those with-
out AF (respectively 39.1% and 43.5%, p = 0.46, OR 0.83
[95% CI: 0.41, 1.69]). This was also the case for the meta-
bolic syndrome (41.3% among those with and 31.5%
among those without AF, p = 0.24).
HbA1c were however higher among those with AF (5.9%
vs 5.7%, p = 0.05) and there was a significant higher incre-
mental AUC between the 1st and 2nd h of the OGTT (193.2Cardiovascular Diabetology 2008, 7:28 http://www.cardiab.com/content/7/1/28
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Table 1: Background data for the 75-year old study participants (n = 154).
Atrial fibrillation No atrial fibriallation Chi-square/df/p or t/d.f/p
Gender (male/female) 34 (31.8%)/12 (25.5%) 73 (68.2%)/35 (74.5%) 0.608/1/0.44
BMI (kg/m2) 25.3 ± 3.7 25.4 ± 3.2 -0.176/145/0.86
Waist (cm) 93.5 ± 11.7 91.6 ± 10.9 0.936/151/0.35
SBP (mmHg) 143 ± 21 147 ± 16 -1.169/152/0.24
DBP (mmHg) 82 ± 10 81 ± 9 1.069/152/0.29
Concomitant disorders, n (%)
Hypertension 38 (82.6%) 83 (76.9%) 0.635/1/0.43
MI 6 (13.0%) 11 (10.2%) 0.268/1/0.60
HF 7 (15.2)* 0 (0.0%) < 0.001 (Fisher)
Valve surgery 3 (6.5%)* 1 (0.9%) 0.046 (Fisher)
CABG/PCI 6 (13.0%) 8 (7.4%) 1.240/1/0.27
Cerebrovascular disease 5 (10.9%)* 2 (1.9%) 0.025 (Fisher)
Medication, n (%)
Warfarin 33 (76.1%)* 4 (3.7%) < 0.001 (Fisher)
Acetylic acid 3 (6.5%) 33 (30.6%)* 0.001 (Fisher)
Digitoxin 8 (17.4)* 0 (0%) < 0.001 (Fisher)
Verapamil 10 (21.7)* 2 (1.9) < 0.001 (Fisher)
Other Ca2+ blockers 4 (8.7) 11 (8.7) 1.000 (Fisher)
Beta blockers 14 (30.4%)* 16 (14.8%) 5.018/1/0.03*
ACE inhibitor 12 (26.1%)* 13 (12.0%) 4.683/1/0.03*
AT-II antagonist 13 (28.3%)* 13 (12.0%) 6.051/1/0.01*
Diuretics 12 (26.1%)* 5 (4.6%) 15.125/1/<0.001*
Statins 18 (39.1)* 19 (17.6) 8.198/1/0.01*
Laboratory parameters
Total leukocyte count (109) 6.0 ± 1.3 6.2 ± 1.6 -0.52/140/0.61
Creatinine (μmol/l) 84 ± 21 80 ± 23 0.93/137/0.35
Total cholesterol (mmol/l) 5.2 ± 1.0* 5.6 ± 1.1 -2.326/140/0.02*
Triglycerides (mmol/l) 1.1 ± 0.8 1.1 ± 0.6 0.162/140/0.87
HDL-cholesterol (mmol/l) 1.7 ± 0.6 1.7 ± 0.5 0.443/140/0.66
LDL-cholesterol (mmol/l) 2.9 ± 0.9* 3.4 ± 1.0 -2.713/139/0.01
*: p ≤ 0.05. Abbreviations: BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, MI – myocardial infarction, HF – 
heart failure, CABG – coronary artery by-pass graft, PCI – percutaneous coronary intervention, Ca2+-calcium, ACE – angiotensin converting 
enzyme, AT-II – angiotensin II, HDL – high density lipoprotein, LDL – low density lipoprotein.
Table 2: Glucometabolic parameters, OGTT results and prevalence of the metabolic syndrome in subjects with and without atrial 
fibrillation.
Atrial fibrillation No atrial fibriallation Chi-square/df/p or t/d.f/p
N4 6 1 0 8
HbA1c (%) 5.9 ± 0.3* 5.7 ± 0.4 1.953/139/0.05
Insulin (pmol/l) 98 ± 67 90 ± 39 0.887/120/0.38
HOMA-IR 4.35 ± 3.4 4.0 ± 1.9 0.730/120/0.47
Fasting glucose (mmol/l) 5.3 ± 0.6 5.3 ± 0.6 0.156/152/0.88
Delta 1-h glucose (mmol)l) 4.3 ± 2.2 3.9 ± 1.9 -1.299/152/0.20
Delta 2-h glucose (mmol/l) 2.0 ± 2.2 1.4 ± 1.6 -0.167/152/0.10
AUC Baseline-60 minutes 129.7 ± 65.6 116.1 ± 57.2 -1,299/152/0.20
AUC 60–120 minutes 193.2 ± 102.0* 161.1 ± 85.5 -2,010/152/0.05
OGTT results and the metabolic syndrome, n (%)
NGT 28 (60.9%) 61 (56.5%) 6.143/2/0.46
Prediabetes 12 (26.1%) 43 (39.8%)
DM 6 (13.0%) 4 (3.7%)
Metabolic syndrome 19 (41.3%) 34 (31.5%) 1.379/1/0.240
*: p ≤ 0.05 Abbreviations: HbA1c – Haemoglobin A1c, HOMA-IR – homeostasis model assessment for insulin resistance, h – hour, AUC – area 
under the curve, OGTT – oral glucose tolerance test, NGT – normal glucose tolerance, DM – diabetes mellitusCardiovascular Diabetology 2008, 7:28 http://www.cardiab.com/content/7/1/28
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vs 161.1, p = 0.05), as well as a trend towards higher glu-
cose levels at 1 h and 2 h during the OGTT (Figure 1).
In the AF group (Figure 2), subjects with AF duration ≥ 5
years (median value) had a statistical significant higher
prevalence of abnormal glucose metabolism (61.1% [DM
22.2%, prediabetes 38.9%], OR 4.7 [95% CI: 1.3, 16.9])
as compared to those with AF duration < 5 years (25%
[DM 7.1%, prediabetes 17.9%]) (p = 0.0014). This preva-
lence tended even to be higher than among the 75-year
old subjects without AF (p = 0.17, OR 2.04 [95% CI: 0.73,
5.66]). This association was further supported by a signif-
icant positive correlation between the duration of AF and
HbA1c (r = 0.408, p = 0.005) as well as fasting glucose lev-
els (r = 0.353, p = 0.016), although no significant relation
was seen for 1 h glucose, 2 h glucose, fasting insulin levels
or HOMA-IR.
Interestingly, this increased prevalence among subjects
with AF ≥ 5 years was not accompanied by a significant
increased prevalence of the metabolic syndrome (without
AF 31.5%, AF < 5 years 35.7%, AF ≥ 5 years 50.0%, p =
0.306), HOMA-IR (3.99, 4.01 and 5.16), use of CV medi-
cations or concomitant CV complications, although the
prevalence of heart failure was higher in the above median
group (0.0%, 3.6%, 33.3%, p < 0.001). In a logistic regres-
sion analysis however, neither heart failure nor valve sur-
gery had an impact on the dysglycaemia prevalence
according to median AF duration.
In the AF group, among those classified as having NGT,
prediabetes or DM, mean AF duration (min, max) also
differed significantly (p = 0.013), were this respectively
were 4 ± 4 (0, 14), 9 ± 8 (0, 28) and 9 ± 6 (3, 20) years (p
= 0.016). In a post-hoc (Bonferroni) analysis the differ-
ences reached statistical significances in the prediabetes vs
the NGT group (p = 0.046) while a borderline significance
was found between NGT vs DM (p = 0.096).
Discussion
In this study we found an increased glycaemic burden
among 75-year old subjects with AF as compared to
matched subjects without AF and that the prevalence of
previously undiagnosed prediabetes or DM among sub-
Glucose values of the OGTT before and at 1 and 2 hours Figure 1
Glucose values of the OGTT before and at 1 and 2 hours. The figure indicates mean ± standard error glucose values 
among subjects with AF (white circles) and without AF (black circles) as well as individual results. The dots to the right of the 
circles are the results in the AF group whereas dots to the left indicate results for the non-AF group. Abbreviation: SE: stand-
ard error, OGTT: oral glucose tolerance test.
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jects in whom AF duration ≥ 5 years were high (61.1%),
in fact at comparable rate as in patients with ischemic CV
complications [18,19]. Hence, our findings suggest that
undiagnosed abnormal glucose metabolism should pro-
actively be investigated in older subjects with AF duration
≥ 5 years.
Chronic hyperglycaemia may contribute to the AF burden
[8-11] in several ways, and one as recently described,
could be through the activation of the AGE (advanced gly-
cation endproduct) – RAGE (receptors for AGE) system
and the up regulation of circulating tissue growth factors
(CTGF) that may promote atrial structural remodelling
[25]. A detection of dysglycaemia could therefore be of
importance if a reduction in glycaemic burden could
modulate the AF burden or transistion rate. Although this
remains to be further proven, some, yet limited, literature
in fact yields support [12,13,15].
Equally, or more, important though is that further glycae-
mic deterioration could be prevented by pharmacological
or non-pharmacological means [26]. The glycaemic dete-
rioration leads to an aggravation of risk for CV complica-
tions, which among subjects with AF, stroke is of
particular concern [16,17], underscored by recommenda-
tion of AF to strongly be considered in patients with DM
who present with stroke and no definite cause [9]. With
the increasing prevalence of both DM and AF worldwide
[5-7], especially among the elderly, an increase in the
number of strokes and hospital admissions in this popu-
lation is likely, thereby providing a large burden on the
health care.
One potential reason for that long standing AF increases
prevalence of an abnormal glucose metabolism could be
related to an activation of inflammation, an early mani-
festation of AF as well as DM, hence potentially also being
a common soil for this association. This was first under-
scored in a study relating AF and inflammation in a bur-
den dependent manner, i.e., patients with persistent AF
had higher levels of CRP than subjects with paroxsystic or
no AF [3]. Interestingly, this also seems to be the case for
dysglycaemia [18]. Given that chronic inflammation
mediate its effect over time, it is also plausible that inflam-
mation associated with AF over time could have an
adverse impact on glucose metabolism.
Undiagnosed dysglycaemia according to duration of AF Figure 2
Undiagnosed dysglycaemia according to duration of AF. Prevalence of undiagnosed dysglycaemia in subjects with AF < 
5 years and in subjects with AF ≥ 5 years.
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Another possibility for that AF increase the glycaemic bur-
den is that AF may render subjects with poorer exercise
capacity [27] hence restricting them in reaching advised
levels of leisure time physical activity. Reduced physical
activity is a well established risk factor for both diabetes
and prediabetes [26], but moreover, could also contribute
to an accelerated conversion rate from prediabetic states
to DM [26].
Limitations
This study has some limitations a part from the relatively
small sample size and the exclusive inclusion of 75-year
old subjects, although the latter also could be considered
strength of the study. Differences in vascular co-morbidity
found between the groups make it harder to interpret the
relative contribution of AF respective CV complications
on dysglycaemia. The different rates of beta-blocking
agent use and diuretics could also influence the OGTT-
results adversely. However, the analyses of subjects with
AF according to median AF duration revealed no differ-
ences in the use of CV medications or concomitant CV
complications (only heart failure), yet a significant differ-
ence in the prevalence of previously undiagnosed dysgly-
caemia was noted.
In this study a higher use of statins and compounds block-
ing the renin-angiotensin system were found in the AF
group. Such use have been associated with lower preva-
lence of DM [28], hence this could reduce the impact of
AF on chronic hyperglycaemia. However, the glucose low-
ering abilities of these medications are probably small,
although the AF group had decreased levels of LDL-cho-
lesterol as well as a tendency to lower blood pressure.
Conclusion
In conclusion, this study suggests that undiagnosed DM
and prediabetes among older subjects with AF should pro-
actively be assessed if duration of AF ≥ 5 years. Further
studies are needed to clarify how long standing AF may in
some way induce chronic hyperglycaemia, and if glucose
lowering strategies reduces the AF burden.
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